Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab SC Maintenance in Ulcerative Colitis (VISIBLE 1)
NCT02611830Phase 3Completed
- Sponsor
- Takeda
- Start
- Dec 2015
- Primary completion
- May 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 31
01
Overview
A Phase 3 trial of vedolizumab in ulcerative colitis (UC), sponsored by Takeda. Started Dec 2015; status: completed.
02
Drugs
vedolizumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02611830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02611830.